• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Famotidine and Coronavirus Disease 2019.法莫替丁与2019冠状病毒病
Gastroenterology. 2021 Jul;161(1):360-361. doi: 10.1053/j.gastro.2020.12.044. Epub 2020 Dec 30.
2
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
3
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
4
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
5
Famotidine Against SARS-CoV2: A Hope or Hype?法莫替丁对新型冠状病毒2：希望还是炒作？
Mayo Clin Proc. 2020 Aug;95(8):1797-1799. doi: 10.1016/j.mayocp.2020.05.027. Epub 2020 Jun 6.
6
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
7
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
8
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.西替利嗪-法莫替丁双重阻断组胺受体可减轻 COVID-19 患者的肺部症状。
Pulm Pharmacol Ther. 2020 Aug;63:101942. doi: 10.1016/j.pupt.2020.101942. Epub 2020 Aug 29.
9
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.法莫替丁在 2019 年新型冠状病毒疾病中的再利用：系统评价。
Drug Res (Stuttg). 2021 Jul;71(6):295-301. doi: 10.1055/a-1397-6763. Epub 2021 Mar 23.
10
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.

引用本文的文献

1
Role of H receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial.H受体阻滞剂法莫替丁对新型冠状病毒肺炎患者临床康复的作用：一项随机对照试验。
World J Clin Cases. 2022 Aug 16;10(23):8170-8185. doi: 10.12998/wjcc.v10.i23.8170.
2
A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature.酸抑制药物、COVID-19及高度多样化文献的鸟瞰（再审视）
Front Pharmacol. 2021 Aug 11;12:700703. doi: 10.3389/fphar.2021.700703. eCollection 2021.

本文引用的文献

1
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.法莫替丁治疗住院 COVID-19 患者的疗效比较。
Am J Gastroenterol. 2021 Apr;116(4):692-699. doi: 10.14309/ajg.0000000000001153.
2
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.法莫替丁的使用与30天死亡率无关：一项对来自大型医疗保健系统的7158例2019冠状病毒病住院患者的粗匹配精确研究。
Gastroenterology. 2021 Feb;160(3):919-921.e3. doi: 10.1053/j.gastro.2020.10.011. Epub 2020 Oct 12.
3
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.法莫替丁改善住院 COVID-19 患者结局的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):848. doi: 10.1186/s13063-020-04773-6.
4
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.西替利嗪-法莫替丁双重阻断组胺受体可减轻 COVID-19 患者的肺部症状。
Pulm Pharmacol Ther. 2020 Aug;63:101942. doi: 10.1016/j.pupt.2020.101942. Epub 2020 Aug 29.
5
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.法莫替丁对 COVID-19 住院患者临床结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
6
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.法莫替丁在非住院 COVID-19 患者中的应用及定量症状跟踪：一项病例系列研究。
Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.
7
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
8
Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.香港队列粪便样本中 SARS-CoV-2 感染的胃肠道表现及病毒载量：系统评价与荟萃分析
Gastroenterology. 2020 Jul;159(1):81-95. doi: 10.1053/j.gastro.2020.03.065. Epub 2020 Apr 3.

Famotidine and Coronavirus Disease 2019.

作者信息

Freedberg Daniel E, Wang Timothy C, Abrams Julian A

机构信息

Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, New York.

出版信息

Gastroenterology. 2021 Jul;161(1):360-361. doi: 10.1053/j.gastro.2020.12.044. Epub 2020 Dec 30.

DOI:10.1053/j.gastro.2020.12.044
PMID:33387529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833856/
Abstract
摘要